10-K: Arbutus Biopharma Secures Moderna Settlement, Advances HBV Pipeline

Arbutus Biopharma reports a significant patent settlement with Moderna for $950M noncontingent payment, while advancing its HBV pipeline and undergoing substantial corporate restructuring.

Summary

• Arbutus Biopharma Corporation (Arbutus) entered into a settlement agreement with Moderna, Inc. on March 3, 2026, resolving all patent infringement litigation.
• Moderna will make an aggregate $950.0 million noncontingent lump sum payment to Arbutus and Genevant Sciences GmbH (Genevant) on or before July 8, 2026.
• An additional aggregate contingent lump sum payment of $1.3 billion is due from Moderna upon a favorable ruling in a limited appeal related to 28 U.S.C. 1498 (the Moderna 1498 Appeal).
• Arbutus is entitled to receive 20% of the noncontingent settlement payment (after deduction of litigation costs) from Genevant, in addition to its approximately 16% equity ownership in Genevant.
• The company is evaluating a return of capital to shareholders in the third quarter of calendar year 2026, following receipt of its portion of the noncontingent payment.
• Arbutus is pursuing an ongoing patent infringement lawsuit against Pfizer Inc. and BioNTech SE for their use of its patented lipid nanoparticle (LNP) technology, with a generally favorable claim construction ruling issued in September 2025.
• A complaint was filed against the United States on March 19, 2026, in the Court of Federal Claims, seeking compensation for Moderna's infringement for vaccine doses sold to the U.S. Government.
• The company underwent significant restructuring in 2024 and Q1 2025, ceasing all discovery efforts, halting preparations for a potential IM-PROVE III clinical trial, and reducing its workforce by a total of 57% in 2025.
• Restructuring charges of $12.9 million were incurred in 2025, including costs related to exiting its corporate headquarters in Warminster, Pennsylvania, and discontinuing in-house scientific research.
• The Qilu License Agreement was mutually terminated in June 2025, resulting in Arbutus regaining global rights for imdusiran and recognizing $10.4 million in previously deferred revenue in 2025.
• The company's lead product candidates for chronic hepatitis B (cHBV) are imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor.
• Imdusiran Phase 2a clinical trials showed 10 patients achieved functional cure and 47% (49/105) of all Phase 2a patients achieved functional cure or remained off nucleos(t)ide analogue (NA) therapy for at least 48 weeks.
• AB-101 Phase 1a/1b clinical trial demonstrated general tolerability and high receptor occupancy, but the FDA placed a clinical hold on its IND application in the United States.
• Net loss for the fiscal year ended December 31, 2025, was $33.5 million, a significant reduction from $69.9 million in 2024.
• Total revenue increased to $14.083 million in 2025 from $6.171 million in 2024, primarily due to deferred revenue recognition from the Qilu agreement.
• Research and development expenses decreased by $28.8 million in 2025 to $25.241 million, and general and administrative expenses decreased by $6.2 million to $15.893 million.
• Cash, cash equivalents, and investments in marketable securities totaled $91.5 million as of December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to the significant Moderna settlement and favorable progress in the Pfizer/BioNTech litigation, which substantially enhance the company's financial outlook and intellectual property strength. While clinical holds and ongoing losses present challenges, the strategic focus and promising HBV pipeline data provide a strong foundation for future growth.

Positives

• Secured a significant patent settlement with Moderna, including a noncontingent $950.0 million payment and a potential $1.3 billion contingent payment, substantially improving liquidity.
• Received a generally favorable claim construction ruling in September 2025 in the ongoing patent infringement lawsuit against Pfizer/BioNTech, strengthening its intellectual property position.
• Imdusiran clinical data showed promising results, with 10 patients achieving functional cure and 47% of Phase 2a patients remaining off NA therapy for at least 48 weeks, indicating potential for a functional cure in cHBV.
• AB-101 Phase 1a/1b trial demonstrated general tolerability and high receptor occupancy, suggesting a viable path for immune activation in cHBV treatment.
• Regained global rights for imdusiran after mutually terminating the Qilu License Agreement, providing full control over its development and commercialization.
• Achieved a significant reduction in net loss, from $69.9 million in 2024 to $33.5 million in 2025, reflecting improved financial performance.
• Increased total revenue by $7.9 million in 2025, primarily due to the recognition of deferred revenue from the Qilu agreement.
• Implemented substantial cost management efforts, leading to significant reductions in research and development and general and administrative expenses.
• Launched a new Scientific Advisory Board (SAB) with globally-recognized leaders to advise on the cHBV pipeline strategy, enhancing strategic guidance.

Negatives

• Continued to incur operating losses, with a net loss of $33.5 million in 2025, contributing to an accumulated net deficit of approximately $1.4 billion since inception.
• The $1.3 billion contingent settlement payment from Moderna is subject to a limited appeal and potential repayment, introducing significant financial uncertainty.
• The FDA placed a clinical hold on the AB-101 IND application in the United States, potentially delaying its clinical development program.
• Underwent substantial workforce reductions (40% in 2024, an additional 57% in Q1 2025) as part of restructuring, which can impact morale and institutional knowledge.
• Exited corporate headquarters and discontinued in-house scientific research, potentially limiting future discovery efforts and innovation.
• The EPO Board of Appeal revoked European patent EP 2279254 in January 2026, although the company plans to appeal and does not expect an impact on the Pfizer/BioNTech litigation.
• Anticipates a continued decrease in license royalty revenue from ONPATTRO due to cannibalization by Alnylam's next-generation RNAi product, AMVUTTRA.

Risks

• Involvement in patent infringement lawsuits against large, well-capitalized companies (Pfizer/BioNTech) and the United States requires substantial resources with uncertain outcomes and lengthy appeal processes.
• The $1.3 billion contingent settlement payment from Moderna is subject to a limited appeal and potential repayment, creating significant financial uncertainty and potential liquidity impact.
• Product candidates are in early stages of development, with no commercialized products or product revenues to date, making future success highly speculative.
• Requires substantial additional capital to fund operations, which may lead to shareholder dilution or operational restrictions if not available.
• Clinical trials are expensive, time-consuming, and difficult to design and implement, with uncertain outcomes; preclinical and interim data are not necessarily predictive of later success.
• Limited operational resources may lead to pursuing particular product candidates while failing to advance others with greater potential.
• The FDA may not accept data from clinical trials conducted outside the United States, potentially requiring additional costly and time-consuming trials.
• Regulatory agencies' review and approval times for product candidates are unpredictable, potentially delaying or preventing commercialization.
• Product candidates may cause undesirable side effects, leading to clinical trial challenges, regulatory hurdles, or limited commercial viability.
• Difficulty in enrolling patients in clinical trials could delay or prevent their completion.
• Resolution of the FDA clinical hold on the AB-101 IND application may take considerable time and expense, with no assurance of removal.
• Approved drug products remain subject to ongoing regulatory requirements and oversight, including manufacturing, quality control, and safety surveillance.
• Faces significant competition from other biotechnology and pharmaceutical companies targeting HBV, many with greater resources and experience.
• Ability to generate product revenues and achieve profitability is largely dependent on the future commercial success of HBV product candidates, which is uncertain.
• Risk of substantial liabilities from product liability lawsuits, potentially requiring commercialization limits or exceeding insurance coverage.
• Uncertainty regarding coverage and adequate reimbursement for product candidates from third-party payors, which could hinder profitable sales.
• Subject to complex United States and Canadian healthcare fraud and abuse laws and regulations, potentially leading to criminal sanctions, civil penalties, and reputational harm.
• Dependence on license agreements for a significant portion of revenues, with risks of unsuccessful collaborations or unreceived milestone/royalty payments.
• Conflicts with licensing partners may arise, potentially affecting business interests.
• Reliance on third parties to conduct clinical trials and manufacture product candidates exposes the company to risks of delays, quality issues, or higher costs.
• Other entities may assert patent rights that prevent the development or commercialization of products.
• Certain patents and patent applications have been challenged and found invalid (e.g., EPO 254 Patent), and future challenges may occur, adversely affecting intellectual property protection.
• Substantial costs from litigation or other proceedings relating to patent and other intellectual property rights, with no guarantee of success.
• Confidentiality agreements may not adequately prevent disclosure of trade secrets and other proprietary information.
• Concentration of common share ownership (e.g., Roivant Sciences Ltd. holding ~20%) may limit the ability of other shareholders to influence corporate matters.
• Incorporation in Canada with assets in both Canada and the United States may make it difficult for investors to enforce judgments.
• Potential for adverse United States federal income tax consequences for United States shareholders if deemed a passive foreign investment company (PFIC).
• Canadian laws and corporate articles could delay or deter a change of control.
• Potential liability from the controlled use of hazardous and radioactive materials in development processes.
• Business, reputation, and operations could suffer from information technology system failures or cybersecurity incidents.
• Strategic alliances or collaborations may harm financial condition, results of operations, or cash flows, or lead to shareholder dilution.

Future Outlook

Arbutus is evaluating a return of capital to shareholders in the third quarter of calendar year 2026, following the receipt of its portion of the noncontingent Moderna settlement payment. The company expects to maintain its reduced net cash burn in 2026 due to ongoing cost management and organizational changes. Substantial additional funds will be required for the active development of its pipeline products and technologies. The company anticipates a continued decrease in license royalty revenue from ONPATTRO due to cannibalization by Alnylam's next-generation product. Arbutus plans to file a petition for review by the Enlarged Board of Appeal of the EPO regarding the revocation of the 254 Patent. New EU pharmaceutical legislation is expected to apply beginning in mid-2028, which could impact regulatory data protection.

Management Comments

• "We are currently evaluating a return of capital to our shareholders in the third quarter of calendar year 2026, following the receipt of our portion of the Noncontingent Settlement Payment."
• "With these organizational changes and our ongoing cost management efforts, we significantly reduced our net cash burn in 2025 when compared to 2024."
• "Our strategy is focused on maximizing opportunities for our cHBV development programs and, through our exclusive license with Genevant, our in-house developed LNP technology."
• "We continue to protect and defend our intellectual property, which is the subject of our ongoing lawsuit against Pfizer/BioNTech for their use of our patented LNP technology in their COVID-19 mRNA-LNP vaccines."
• "We believe there is a compelling market opportunity for an HBV curative regimen."
• "We believe patients can see significant benefits with imdusiran even without functional cure if they are well enough to be able to discontinue NA therapy and maintain viral suppression."
• "We disagree with the outcome [of the EPO 254 Patent revocation], and upon receipt of the written decision, we plan to file a petition for review by the Enlarged Board of Appeal of the EPO."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry, particularly in infectious diseases like cHBV, is highly competitive with numerous large and small companies developing various therapeutic approaches. The significant patent litigation surrounding LNP technology highlights the intense intellectual property landscape in mRNA vaccine development. The trend of cost containment in healthcare and evolving regulatory frameworks, such as the EU pharmaceutical legislation revision and US healthcare reforms (IRA, OBBBA), will continue to pressure drug pricing and reimbursement, impacting commercial viability for new products.

Comparison to Industry Standards

• Current cHBV treatments, such as IFN and NA therapies, typically have low functional cure rates (fewer than 10%) and often require lifelong treatment, highlighting a significant unmet medical need that Arbutus's imdusiran aims to address.
• Imdusiran's functional cure rate of 50% in HBeAg negative patients with baseline HBsAg levels less than 1000 IU/mL in the IM-PROVE I trial, and 25% in the IM-PROVE II trial (with low dose nivolumab) for similar patients, suggests a potentially superior outcome compared to existing standard-of-care options.
• The observed durability of imdusiran, enabling 41 patients to remain off NA therapy for at least 48 weeks and some for 82 to 134 weeks, represents a notable improvement over the lifelong treatment often required with current NA therapies.
• The LNP technology, initially licensed to Alnylam for ONPATTRO, has proven foundational for mRNA vaccines (e.g., Moderna, Pfizer/BioNTech), demonstrating its critical role and broad applicability in nucleic acid delivery, a key industry trend.
• The decline in ONPATTRO sales due to Alnylam's next-generation product, AMVUTTRA (vutrisiran), reflects the rapid innovation and competitive pressures within the RNAi therapeutic space, where companies continuously strive for improved efficacy and patient convenience.

Management Changes

Corporate Governance

Legal Proceedings

• **Patent Infringement Litigation vs. Pfizer and BioNTech**: Lawsuit filed April 4, 2023, in the U.S. District Court for the District of New Jersey, seeking damages for infringement of five U.S. patents related to LNP technology in COVID-19 mRNA-LNP vaccines. A claim construction ruling in September 2025 was generally favorable, and parties are awaiting further scheduling.
• **Patent Infringement Litigation vs. Moderna**: Lawsuit filed February 28, 2022, in the U.S. District Court for the District of Delaware, seeking damages for infringement of six U.S. patents for Moderna's COVID-19 vaccine. Five international lawsuits were also filed on March 3, 2025.
• **Moderna Settlement Agreement**: Entered into on March 3, 2026, resolving all patent infringement litigation and patent revocation proceedings involving Moderna. Moderna will make an aggregate $950.0 million noncontingent lump sum payment by July 8, 2026, and an additional aggregate contingent lump sum payment of $1.3 billion upon a favorable ruling in the Moderna 1498 Appeal.
• **Lawsuit vs. United States**: A complaint was filed on March 19, 2026, in the U.S. Court of Federal Claims, seeking compensation for Moderna's infringement for vaccine doses sold to the U.S. Government and deemed provided directly to U.S. Government employees. It also includes a protective request for other vaccine doses where 1498 bars claims against Moderna.
• **Moderna and Merck European Oppositions (EP 2279254)**: Moderna and Merck filed Notices of Opposition on April 5, 2018. The EPO Board of Appeal verbally decided to revoke the 254 Patent on January 15, 2026. Arbutus plans to file a petition for review. Moderna withdrew from this proceeding in March 2026 due to the settlement, and the decision is not expected to impact the Pfizer/BioNTech litigation.
• **Moderna and Merck European Oppositions (EP 4241767)**: Moderna filed a revocation action on April 29, 2025, followed by three additional revocation actions by Merck, Arrowhouse GmbH, and Keltie LLP in July 2025. Initial briefing is complete, and an initial hearing date is awaited. Moderna withdrew from this proceeding in March 2026 due to the settlement.

Related Party Transactions

• On August 5, 2025, the company entered into an agreement with Keith Manchester, M.D., for consulting services regarding its development strategy and hepatitis B programs. Dr. Manchester served as a member of the Board until February 24, 2025, making him a related person. In connection with this agreement, an option to purchase 400,000 common shares was granted to Dr. Manchester.

Stakeholder Impact

• **Shareholders**: Potential for a return of capital in Q3 2026 from the Moderna settlement proceeds. The significant settlement and ongoing litigation against Pfizer/BioNTech could lead to increased shareholder value, but also introduce share price volatility. Future equity financings could lead to dilution.
• **Employees**: Experienced significant workforce reductions (40% in 2024, an additional 57% in Q1 2025) due to restructuring, impacting employment stability. The shift to remote work arrangements affects work environment and culture. Stock-based compensation modifications were made for terminated employees.
• **Patients (future)**: The continued development of imdusiran and AB-101 aims to provide a functional cure for chronic hepatitis B, addressing a significant unmet medical need and potentially improving patient outcomes.
• **Partners (Genevant)**: Genevant is a direct beneficiary of the Moderna settlement, sharing in both the noncontingent and contingent payments, which strengthens its financial position and collaboration with Arbutus.
• **Regulatory Authorities**: Ongoing engagement with the FDA and other international regulatory bodies for clinical trials and approvals, with potential impacts on product development timelines and market access.

Next Steps

• Receive the aggregate $950.0 million noncontingent settlement payment from Moderna on or before July 8, 2026.
• Evaluate a potential return of capital to shareholders in the third quarter of calendar year 2026.
• Await further scheduling in the ongoing Pfizer/BioNTech patent infringement litigation.
• Moderna may file a limited appeal related to 28 U.S.C. 1498 (the Moderna 1498 Appeal).
• File a petition for review by the Enlarged Board of Appeal of the EPO regarding the revocation of the 254 Patent.
• Continue to evaluate and refine potential Phase 2b clinical trial designs for imdusiran.
• Address FDA concerns to resolve the clinical hold on the AB-101 IND application.
• Await an initial hearing date for the revocation actions against the 767 patent.
• The final text of the European Union pharmaceutical reform proposal is expected to be endorsed and published in the first half of 2026, with new legislation expected to apply beginning in mid-2028.

Key Dates

Recommendation

The substantial noncontingent settlement of $950 million from Moderna, with a potential additional $1.3 billion, significantly de-risks Arbutus's financial position and provides a strong cash runway. The favorable claim construction ruling in the Pfizer/BioNTech litigation further strengthens the company's intellectual property assets, which are foundational to mRNA technology. While the company has undergone significant restructuring and faces ongoing clinical development risks, the improved liquidity and strategic focus on its promising cHBV pipeline (imdusiran and AB-101) position it for potential long-term value creation. The planned return of capital to shareholders also indicates a commitment to shareholder value.

Keywords

Arbutus Biopharma, ABUS, Moderna Settlement, Patent Infringement, HBV, Hepatitis B, Imdusiran, AB-729, RNAi Therapeutic, AB-101, PD-L1 Inhibitor, LNP Technology, Clinical Trials, Biopharmaceutical, Restructuring, Financial Results, Intellectual Property, Nasdaq